NCT01519531

Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects

A Randomized, Double-blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Madrigal Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a single-center, randomized, double-blind, placebo-controlled, ascending multiple-dose study of VIA-3196 to evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects. Study dosing is organized into cohorts corresponding to escalating doses of VIA-3196 or matching placebo. Subjects will be dosed daily for 14 days.

Conditions

• Drug Safety

Interventions

Type	Name	Description
DRUG	Placebo	Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm
DRUG	VIA-3196	Oral, daily dosing for 14 days

Timeline

• Start date: 2012-01-01
• Primary completion: 2012-11-01
• Completion: 2012-11-01
• First posted: 2012-01-27
• Last updated: 2012-12-06

Locations

1 site across 1 country: United States